Omeros Corporation (OMER)
Market Cap | 223.09M |
Revenue (ttm) | n/a |
Net Income (ttm) | -121.30M |
Shares Out | 57.94M |
EPS (ttm) | -1.97 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 126,547 |
Open | 3.960 |
Previous Close | 3.950 |
Day's Range | 3.845 - 3.960 |
52-Week Range | 0.920 - 5.840 |
Beta | 1.36 |
Analysts | Hold |
Price Target | n/a |
Earnings Date | Aug 7, 2024 |
About OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunog... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/8/e/conf1-2461357.jpg)
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, J...
![](https://cdn.snapi.dev/images/v1/k/r/press9-2459033.jpg)
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending th...
![](https://cdn.snapi.dev/images/v1/r/n/press18-2433261.jpg)
Omeros Corporation Reports First Quarter 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
![](https://cdn.snapi.dev/images/v1/k/m/conf6-2423960.jpg)
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024...
![](https://cdn.snapi.dev/images/v1/2/c/press11-2421610.jpg)
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria sub...
![](https://cdn.snapi.dev/images/v1/c/h/press7-2350725.jpg)
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
![](https://cdn.snapi.dev/images/v1/a/g/conf17-2343814.jpg)
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 202...
![](https://cdn.snapi.dev/images/v1/z/q/press1-2283741.jpg)
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell tr...
![](https://cdn.snapi.dev/images/v1/x/x/press4-2255589.jpg)
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded intere...
![](https://cdn.snapi.dev/images/v1/t/m/press16-2150931.jpg)
Omeros Corporation Reports Third Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
![](https://cdn.snapi.dev/images/v1/5/y/conf14-2141376.jpg)
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, ...
![](https://cdn.snapi.dev/images/v1/n/q/press18-2138985.jpg)
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic st...
![](https://cdn.snapi.dev/images/v1/d/r/press14-2136360.jpg)
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pat...
![](https://cdn.snapi.dev/images/v1/a/n/press13-2110981.jpg)
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for...
![](https://cdn.snapi.dev/images/v1/k/m/biotech30-2104393.jpg)
Omeros to terminate kidney disease trial as therapy fails late-stage study
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
![](https://cdn.snapi.dev/images/v1/p/a/press3-2104288.jpg)
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
![](https://cdn.snapi.dev/images/v1/o/y/press20-2014541.jpg)
Omeros Corporation Reports Second Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
![](https://cdn.snapi.dev/images/v1/q/5/conf9-2007181.jpg)
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before...
![](https://cdn.snapi.dev/images/v1/s/r/press19-1930070.jpg)
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress...
![](https://cdn.snapi.dev/images/v1/x/s/press20-1916888.jpg)
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead MASP-3 ...
![](https://cdn.snapi.dev/images/v1/d/t/press6-1880562.jpg)
Omeros Corporation Reports First Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
![](https://cdn.snapi.dev/images/v1/q/f/conf18-1872820.jpg)
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 202...
![](https://cdn.snapi.dev/images/v1/n/y/press17-1852351.jpg)
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead ...
![](https://cdn.snapi.dev/images/v1/c/g/press7-1830616.jpg)
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health...
![](https://cdn.snapi.dev/images/v1/s/k/press8-1794647.jpg)
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...